A decade of targeted therapy for non-small cell lung cancer
Open Access
- 1 May 2017
- journal article
- Published by Heighten Science Publications Corporation
- Vol. 1 (1), 023-027
- https://doi.org/10.29328/journal.jprr.1001005
Abstract
No abstract availableThis publication has 38 references indexed in Scilit:
- CeritinibAnnals of Pharmacotherapy, 2014
- Novartis' lung cancer ALK inhibitor approvedNature Biotechnology, 2014
- U.S. Food and Drug Administration Approval Summary: Erlotinib for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 (L858R) Substitution MutationsThe Oncologist, 2014
- Afatinib: First Global ApprovalDrugs, 2013
- Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLCOncoTargets and Therapy, 2013
- Crizotinib: a drug that crystallizes a unique molecular subset of non-small-cell lung cancerExpert Review of Anticancer Therapy, 2012
- Approval Summary: Erlotinib Maintenance Therapy of Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)The Oncologist, 2010
- Gefitinib for the treatment of non-small-cell lung cancerExpert Opinion on Pharmacotherapy, 2010
- Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignanciesClinical Therapeutics, 2006
- FDA Approves Avastin in Combination with Chemotherapy for First-Line Treatment of Most Common Type of Lung CancerCancer Biology & Therapy, 2006